New management algorithms in multiple sclerosis

Current Opinion in Neurology

Volumn 27, Issue 3, 2014, Pages 246-259

  Sorensen, Per Soelberg ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

disease modifying drugs; multiple sclerosis; oral therapies; treatment algorithm

Indexed keywords

ALEMTUZUMAB; BETA1A INTERFERON; FINGOLIMOD; FUMARIC ACID DIMETHYL ESTER; GLATIRAMER; LAQUINIMOD; METHOTREXATE; MITOXANTRONE; NATALIZUMAB; PLACEBO; TERIFLUNOMIDE; BETA INTERFERON; CROTONIC ACID DERIVATIVE; FUMARIC ACID DERIVATIVE; IMMUNOLOGIC FACTOR; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY; PEPTIDE; PROPANEDIOL DERIVATIVE; SPHINGOSINE; TOLUIDINE DERIVATIVE;

ALGORITHM; CHEST TIGHTNESS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; EUROPE; FLU LIKE SYNDROME; GASTROINTESTINAL TOXICITY; HUMAN; INJECTION SITE REACTION; MULTIPLE SCLEROSIS; RELAPSE; REVIEW; UNITED STATES; ANALOGS AND DERIVATIVES; CLINICAL PROTOCOL; MULTIPLE SCLEROSIS, RELAPSING-REMITTING;

ALGORITHMS; ANTIBODIES, MONOCLONAL, HUMANIZED; CLINICAL PROTOCOLS; CROTONATES; FUMARATES; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOSUPPRESSIVE AGENTS; INTERFERON-BETA; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PEPTIDES; PROPYLENE GLYCOLS; SPHINGOSINE; TOLUIDINES;

EID: 84900471238     PISSN: 13507540     EISSN: 14736551     Source Type: Journal    
DOI: 10.1097/WCO.0000000000000096     Document Type: Review

References (62)

1. Potagas C, Giogkaraki E, Koutsis G, et al. Cognitive impairment in different MS subtypes and clinically isolated syndromes.J Neurol Sci 2008; 267:100-106.
2. Comi G, Filippi M, Barkhof F, et al. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet 2001; 357:1576-1582.
3. Fisniku LK, Brex PA, Altmann DR, et al. Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis. Brain 2008; 131 (Pt 3):808-817.
4. Tintore M, Rovira A, Rio J, et al. Baseline MRI predicts future attacks and disability in clinically isolated syndromes. Neurology 2006; 67:968-972.
5. Comi G, Martinelli V, Rodegher M, et al. Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial. Lancet 2009; 374:1503-1511.
6. Comi G, De SN, Freedman MS, et al. Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinat-ing event suggestive of multiple sclerosis (REFLEX): a phase 3 randomised controlled trial. Lancet Neurol 2012; 11:33-41.
7. Jacobs LD, Beck RW, Simon JH, et al. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N Engl J Med 2000; 343:898-904.
8. Kappos L, Polman CH, Freedman MS, et al. Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology 2006; 67:1242-1249.
9. Kinkel RP, Kollman C, O'Connor P, et al. IM interferon beta-1a delays definite multiple sclerosis 5 years after a first demyelinating event. Neurology 2006; 66:678-684.
10. Sorensen PS. Early-stage multiple sclerosis. What are the treatment options? Drugs 2005; 64:2021-2029.
11. Kinkel RP, Dontchev M, Kollman C, et al. Association between immediate initiation of intramuscular interferon beta-1a at the time of a clinically isolated syndrome and long-term outcomes: a 10-year follow-up of the Controlled High-Risk Avonex Multiple Sclerosis Prevention Study in Ongoing Neurological Surveillance. Arch Neurol 2012; 69:183-190.
12. Durelli L, Verdun E, Barbero P, et al. Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN). Lancet 2002; 359:1453-1460.
13. Panitch H, Goodin DS, Francis G, et al. Randomized, comparative study of interferon beta-1a treatment regimens in MS: The EVIDENCE trial. Neurology 2002; 59:1496-1506.
14. Duquette P, Girard M, Despault L, et al. Interferon beta-1b is effective in relapsing-remitting multiple-sclerosis-clinical-results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993; 43: 655-661.
15. Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol 1996; 39:285-294.
16. PRISMS (Prevention of Relapses, Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Randomised doubleblind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet 1998; 352:1498-1504.
17. Johnson KP, Brooks BR, Cohen JA, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology 1995; 45:1268-1276.
18. O'Connor P, Wolinsky JS, Confavreux C, et al. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N Engl J Med 2011; 365: 1293-1303.
19. Kappos L, Comi G, Confavreux C, et al. The efficacy and safety of teriflunomide in patients with relapsing MS: results from TOWER, a phase III, placebo-controlled study. Presented at: Congress of the European Committee for Treatment and Research in Multiple Sclerosis 2012, abstract 153. Mult Scler J 2012; 18 (S4):50-51.
20. Fox RJ, Miller DH, Phillips JT, et al. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med 2012; 367:1087-1097.
21. Gold R, Kappos L, Arnold DL, et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. NEngl JMed 2012; 367:1098-1107.
22. Comi G, Jeffery D, Kappos L, et al. Placebo-controlled trial of oral laquinimod for multiple sclerosis. N Engl J Med 2012; 366:1000-1009.
23. Hartung HP, Gonsette R, Konig N, et al. Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial. Lancet 2002; 360:2018-2025.
24. Polman CH, O'Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006; 354:899-910.
25. Kappos L, Radue EW, O'Connor P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010; 362:387-401.
26. Peter C, Ernst-Wilhelm R, Douglas G, et al. Efficacy and safety of fingolimod in patients with relapsing-remitting multiple sclerosis (RRMS): results from an additional 24-month double-blind, placebo-controlled study (FREEDOMS II study). Neurology 2012; 79:E90-E91.
27. Comi G, Filippi M, Wolinsky JS. European/Canadian multicenter, doubleblind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian Glatiramer Acetate Study Group. Ann Neurol 2001; 49:290-297.
28. Rovaris M, Comi G, Rocca MA, et al. Short-term brain volume change in relapsing-remitting multiple sclerosis: effect of glatiramer acetate and implications. Brain 2001; 124 (Pt 9):1803-1812.
29. Claussen MC, Korn T. Immune mechanisms of new therapeutic strategies in MS: teriflunomide. Clin Immunol 2012; 142:49-56.
30. Wolinsky JS, Narayana PA, Nelson F, et al. Magnetic resonance imaging outcomes from a phase III trial of teriflunomide. Mult Scler 2013; 19:1310-1319.
31. Phillips JT, Fox RJ. BG-12 in multiple sclerosis. Semin Neurol 2013; 33:56-65.
32. Bruck W, Wegner C. Insight into the mechanism of laquinimod action. J Neurol Sci 2011; 306:173-179.
33. Sorensen PS, Deisenhammer F, Duda P, et al. Guidelines on use of antiinterferon-beta antibody measurements in multiple sclerosis-report of an EFNS task force on IFN-beta antibodies in multiple sclerosis. Eur J Neurol 2005; 12:817-827.
34. Massberg S, von Andrian UH. Fingolimod and sphingosine-1-phosphate- modifiers of lymphocyte migration. N Engl J Med 2006; 355:1088-1091.
35. Cohen JA, Coles AJ, Arnold DL, et al. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet 2012; 380:1819-1828.
36. Coles AJ, Twyman CL, Arnold DL, et al. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet 2012; 380:1829-1839.
37. Hartung HP. New cases of progressive multifocal leukoencephalopathy after treatment with natalizumab. Lancet Neurol 2009; 8:28-31.
38. Sorensen PS, Bertolotto A, Edan G, et al. Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab. Mult Scler 2012; 18:143-152.
39. Cohen JA, Barkhof F, Comi G, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 2010; 362:402-415.
40. Coles AJ, Fox E, Vladic A, et al. Alemtuzumab more effective than interferon beta-1a at 5-year follow-up of CAMMS223 clinical trial. Neurology 2012; 78:1069-1078.
41. Marriott JJ, Miyasaki JM, Gronseth G, O'Connor PW. Evidence report: the efficacy and safety of mitoxantrone (Novantrone) in the treatment of multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2010; 74:1463-1470.
42. Martinelli V, Cocco E, Capra R, et al. Acute myeloid leukemia in Italian patients with multiple sclerosis treated with mitoxantrone. Neurology 2011; 77:1887-1895.
43. Mikol DD, Barkhof F, Chang P, et al. Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial. Lancet Neurol 2008; 7:903-914.
44. O'Connor P, Filippi M, Arnason B, et al. 250 mug or 500 mug interferon beta-1b versus 20mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study. Lancet Neurol 2009; 8:889-897.
45. Koch-Henriksen N, Sorensen PS, Christensen T, et al. A randomized study of two interferon-beta treatments in relapsing-remitting multiple sclerosis. Neurology 2006; 66:1056-1060.
46. Vollmer TL, Sorensen PS, Selmaj K, et al. A randomized placebo-controlled phase III trial of oral laquinimod for multiple sclerosis. J Neurol 2014; 261:773-783.
47. Vermersch P, Czlonkowska A, Grimaldi LM, et al. Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trial. Mult Scler 2013. [Epub ahead of print]
48. Lublin FD, Cofield SS, Cutter GR, et al. Randomized study combining interferon and glatiramer acetate in multiple sclerosis. Ann Neurol 2013;73:327-340.
49. Rudick RA, Stuart WH, Calabresi PA, et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med 2006; 354:911-923.
50. Ravnborg M, Sorensen PS, Andersson M, et al. Methylprednisolone in combination with interferon beta-1a for relapsing-remitting multiple sclerosis (MECOMBIN study): a multicentre, double-blind, randomised, placebo-controlled, parallel-group trial. Lancet Neurol 2010; 9:672-680.
51. Sorensen PS, Mellgren SI, Svenningsson A, et al. NORdic trial of oral methylprednisolone as add-on therapy to interferon beta-1a for treatment of relapsing-remitting multiple sclerosis (NORMIMS study): a randomised, placebo-controlled trial. Lancet Neurol 2009; 8:519-529.
52. Cohen JA, Imrey PB, Calabresi PA, et al. Results of the Avonex Combination Trial (ACT) in relapsing-remitting MS. Neurology 2009; 72:535-541.
53. Sorensen PS, Lycke J, Eralinna JP, et al. Simvastatin as add-on therapy to interferon beta-1a for relapsing-remitting multiple sclerosis (SIMCOMBIN study): a placebo-controlled randomised phase 4 trial. Lancet Neurol 2011; 10:691-701.
54. Goodman AD, Rossman H, Bar-Or A, et al. GLANCE: results of a phase 2, randomized, double-blind, placebo-controlled study. Neurology 2009; 72:806-812.
55. Freedman MS, Wolinsky JS, Wamil B, et al. Teriflunomide added to interferon-b in relapsing multiple sclerosis: a randomized phase II trial. Neurology 2012; 78:1877-1885.
56. Sorensen PS, Sellebjerg F, Lycke J, et al., on behalf of the RECYCLINE Study Investigators. No beneficial effect of minocycline as add-on therapy to interferon-beta-1a for the treatment of relapsing-remitting multiple sclerosis: results of a large double-blind, randomised, placebo-controlled trial. Presented at: Congress of the European Committee for Treatment and Research in Multiple Sclerosis, 2012 abstract P941. Mult Scler J 2012; 18 (S4):431-432.
57. Oh J, Calabresi PA. Emerging injectable therapies for multiple sclerosis. Lancet Neurol 2013; 12:1115-1126.
58. Hauser SL, Waubant E, Arnold DL, et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 2008; 358:676-688.
59. Kappos L, Li D, Calabresi PA, et al. Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial. Lancet 2011; 378:1779-1787.
60. Sorensen PS, Lisby S, Grove R, et al. Safety and efficacy of ofatumumab in relapsing-remitting multiple sclerosis: a phase II study. Neurology 2014; 82:573-581.
61. Gold R, Giovannoni G, Selmaj K, et al. Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, doubleblind, placebo-controlled trial. Lancet 2013; 381:2167-2175.
62. Wynn D, Kaufman M, Montalban X, et al. Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta. Lancet Neurol 2010; 9:381-390.